GLP-1 Market Size, Share & Trends Analysis Report By Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist), By Type of Agonist (Single Agonist, Dual Agonist, Tri-agonist), By Molecule Type (Biologic Peptide GLP-1 Agonists, Small-Molecule Non-Peptide GLP-1 Agonists), By Active Compound (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Lixisenatide, Exenatide, Orforglipron, Retatrutide, Survodutide, Other Active Compounds), By Route of Administration (Oral, Parenteral), By Dosing Frequency (Daily, Weekly, Monthly or Extended-Interval), By Delivery System, By Target Indication, By Payer, By Region and By Segments Forecasts, 2025-2034

Report Id: 2592 Pages: 180 Last Updated: 11 March 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of GLP-1 Market -

GLP-1 Market by Type of Molecule -

  • Biologic Peptide GLP-1 Agonists
  • Small-Molecule Non-Peptide GLP-1 Agonists

GLP-1 Market

GLP-1 Market by Active Compound Used -

  • Semaglutide
  • Tirzepatide
  • Dulaglutide
  • Liraglutide
  • Lixisenatide
  • Exenatide
  • Orforglipron
  • Retatrutide
  • Survodutide
  • Other Active Compounds

 GLP-1 Market by Type of GLP-1 Agonist Drugs -

  • Long-acting GLP-1 Agonist
  • Short-acting GLP-1 Agonist  

GLP-1 Market by Type of Agonist -

  • Single agonist
  • Dual agonist
  • Tri-agonist

GLP-1 Market by Route of Administration-

  • Oral
  • Parenteral

GLP-1 Market by Target Indication-

  • Alzheimer’s Disease
  • Non-Alcoholic Steatohepatitis
  • Obesity
  • Sleep Apnea
  • Type 2 Diabetes

GLP-1 Market By Dosing Frequency-

  • Daily
  • Weekly
  • Monthly or Extended-Interval

GLP-1 Market By Delivery System-

  • Disposable Pre-filled Pen
  • Auto-Injector
  • Pre-filled Syringe
  • Oral Tablet / Capsule

GLP-1 Market By Payer-

  • Retail Pharmacy – Commercial Insurance
  • Retail Pharmacy – Government (Medicare / Medicaid)
  • Specialty / Mail-Order Pharmacy
  • Self-Pay

GLP-1 Market by Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Chapter 1.    Methodology and Scope
1.1.    Research Methodology
1.2.    Research Scope & Assumptions

Chapter 2.    Executive Summary

Chapter 3.    Global 3D Printed Satellite Market Snapshot

Chapter 4.    Global 3D Printed Satellite Market Variables, Trends & Scope
4.1.    Market Segmentation & Scope
4.2.    Drivers
4.3.    Challenges
4.4.    Trends
4.5.    Investment and Funding Analysis 
4.6.    Industry Analysis – Porter’s Five Forces Analysis
4.7.    Competitive Landscape & Market Share Analysis
4.8.    Impact of Covid-19 Analysis

Chapter 5.    Market Segmentation 1: by Type of Molecule Estimates & Trend Analysis
5.1.    by Type of Molecule & Market Share, 2024 & 2034
5.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Molecule:

5.2.1.    Biologic Peptide GLP-1 Agonists
5.2.2.    Small-Molecule Non-Peptide GLP-1 Agonists

Chapter 6.    Market Segmentation 2: by Active Compound Used Estimates & Trend Analysis
6.1.    by Active Compound Used & Market Share, 2024 & 2034
6.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Active Compound Used:

6.2.1.    Semaglutide
6.2.2.    Tirzepatide
6.2.3.    Dulaglutide
6.2.4.    Liraglutide
6.2.5.    Lixisenatide
6.2.6.    Exenatide
6.2.7.    Orforglipron
6.2.8.    Retatrutide
6.2.9.    Survodutide
6.2.10.    Other Active Compounds
6.2.11.    Tirzepatide    

Chapter 7.    Market Segmentation 3: by Type of GLP-1 Agonist Drugs Estimates & Trend Analysis
7.1.    by Type of GLP-1 Agonist Drugs & Market Share, 2024 & 2034
7.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of GLP-1 Agonist Drugs:

7.2.1.    Long-acting GLP-1 Agonist
7.2.2.    Short-acting GLP-1 Agonist

Chapter 8.    Market Segmentation 4: by Type of Agonist Estimates & Trend Analysis
8.1.    by Type of Agonist & Market Share, 2024 & 2034
8.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Agonist:

8.2.1.    Single agonist
8.2.2.    Dual agonist
8.2.3.    Tri-agonist

Chapter 9.    Market Segmentation 5: by Route of Administration Estimates & Trend Analysis
9.1.    by Route of Administration & Market Share, 2024 & 2034
9.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:

9.2.1.    Oral
9.2.2.    Parenteral

Chapter 10.    Market Segmentation 6: by Target Indication Estimates & Trend Analysis
10.1.    by Target Indication & Market Share, 2024 & 2034
10.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Indication:

10.2.1.    Alzheimer’s Disease
10.2.2.    Non-Alcoholic Steatohepatitis
10.2.3.    Obesity
10.2.4.    Sleep Apnea
10.2.5.    Type 2 Diabetes

Chapter 11.    Market Segmentation 7: by Dosing Frequency Estimates & Trend Analysis
11.1.    by Dosing Frequency & Market Share, 2024 & 2034
11.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Dosing Frequency:

11.2.1.    Daily
11.2.2.    Weekly
11.2.3.    Monthly or Extended-Interval

Chapter 12.    Market Segmentation 8: by Delivery System Estimates & Trend Analysis
12.1.    by Delivery System & Market Share, 2024 & 2034
12.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery System:

12.2.1.    Disposable Pre-filled Pen
12.2.2.    Auto-Injector
12.2.3.    Pre-filled Syringe
12.2.4.    Oral Tablet / Capsule

Chapter 13.    Market Segmentation 9: by Payer Estimates & Trend Analysis
13.1.    by Target Indication & Market Share, 2024 & 2034
13.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Indication:

13.2.1.    Retail Pharmacy – Commercial Insurance
13.2.2.    Retail Pharmacy – Government (Medicare / Medicaid)
13.2.3.    Specialty / Mail-Order Pharmacy
13.2.4.    Self-Pay

Chapter 14.    3D Printed Satellite Market Segmentation 10: Regional Estimates & Trend Analysis
14.1.    North America

14.1.1.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.1.2.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.1.3.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.1.4.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.1.5.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.1.6.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.1.7.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.1.8.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.1.9.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.1.10.    North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

14.2.    Europe

14.2.1.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.2.2.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.2.3.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.2.4.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.2.5.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.2.6.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.2.7.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.2.8.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.2.9.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.2.10.    Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

14.3.    Asia Pacific

14.3.1.    Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.3.2.    Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.3.3.    Asia-Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.3.4.    Asia-Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.3.5.    Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.3.6.    Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.3.7.    Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.3.8.    Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.3.9.    Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.3.10.    Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

14.4.    Latin America

14.4.1.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.4.2.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.4.3.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.4.4.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.4.5.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.4.6.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.4.7.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.4.8.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.4.9.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.4.10.    Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

14.5.    Middle East & Africa

14.5.1.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
14.5.2.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
14.5.3.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
14.5.4.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
14.5.5.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
14.5.6.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2021-2034
14.5.7.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
14.5.8.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Payer, 2021-2034
14.5.9.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
14.5.10.    Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

Chapter 15.    Competitive Landscape
15.1.    Major Mergers and Acquisitions/Strategic Alliances
15.2.    Company Profiles


15.2.1.    AstraZeneca plc
15.2.2.    Boehringer Ingelheim International GmbH
15.2.3.    Eli Lilly and Company
15.2.4.    Innogen Pharmaceutical Technology Co., Ltd. / Guangzhou Innogen Pharmaceutical Group Co., Ltd.
15.2.5.    Novo Nordisk A/S
15.2.6.    PegBio Co., Ltd.
15.2.7.    Pfizer Inc.
15.2.8.    QL Biopharmaceutical Co., Ltd.
15.2.9.    Roche Holding AG
15.2.10.    Sanofi S.A.
15.2.11.    Sciwind Biosciences Co., Ltd.
15.2.12.    Tonghua Dongbao Pharmaceutical Co., Ltd.
15.2.13.    Viking Therapeutics, Inc.
15.2.14.    Amgen Inc.
15.2.15.    BioLingus GmbH
15.2.16.    D&D Pharmatech Inc.
15.2.17.    Gmax Biopharm LLC
15.2.18.    Hanmi Pharmaceutical Co., Ltd.
15.2.19.    Vivani Medical, Inc.
15.2.20.    vTv Therapeutics Inc.
15.2.21.    Zealand Pharma A/S
15.2.22.    Altimmune, Inc.
15.2.23.    Structure Therapeutics Inc.
15.2.24.    Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
6751
Security Code field cannot be blank!

Frequently Asked Questions

GLP-1 Market Size is valued at USD 50.0 Billion in 2024 and is predicted to reach USD 141.9 Billion by the year 2034

GLP-1 Market is predicted to grow at a 11.1% CAGR during the forecast period for 2025-2034

AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Innogen Pharmaceutical Technology Co., Ltd. / Guangzhou Innogen Pharmaceutical Group Co., Ltd., Novo Nordisk A/S, PegBio Co., Ltd., Pfizer Inc., QL Biopharmaceutical Co., Ltd., Roche Holding AG, Sanofi S.A., Sciwind Biosciences Co., Ltd., Tonghua Dongbao Pharmaceutical Co., Ltd., Viking Therapeutics, Inc., Amgen Inc., BioLingus GmbH, D&D Pharmatech Inc., Gmax Biopharm LLC, Hanmi Pharmaceutical Co., Ltd., Vivani Medical, Inc., vTv Therapeutics Inc., Zealand Pharma A/S, Altimmune, Inc., Structure Therapeutics Inc. and Others

Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target Indication, Dosing Frequency, Delivery System and Payer are the key segment of GLP-1 Market.

North American region is leading the GLP-1 Market

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying